Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality

B. Makubate, P. T. Donnan, J. A. Dewar, A. M. Thompson, C. McCowan

Research output: Contribution to journalArticle

110 Citations (Scopus)

Abstract

Background:Adjuvant endocrine therapy is recommended for women with oestrogen receptor-positive breast cancer, but many women do not take the medication as directed and they stop treatment before completing the standard 5-year duration.Methods:This retrospective cohort study conducted between 1993 and 2008 of all women with incident breast cancer, who are residing in the Tayside region of Scotland, examined adherence to prescribed adjuvant tamoxifen or aromatase inhibitors (AIs). Survival analysis examined the effect of adherence on all-cause mortality, breast cancer death and recurrence, using linked prescribing, cancer registry, clinical cancer audit, hospital discharge and death records.Results:A total of 3361 women with breast cancer were followed for a median 4.47 years (interquartile range (IQR)=2.04-8.55). The median overall adherence was 90% (IQR=90-100%), but the annual adherence reduced after a longer period from diagnosis. Low adherence of <80% was associated with poorer survival (hazard ratios=1.20; 95% confidence interval=1.03-1.40, P=0.019). There was no significant difference for low adherence over the treatment period and recurrence, or breast cancer death, but patients with high annual adherence for 5 years had better outcomes than those with 3 or less.Conclusion:Low adherence to all adjuvant endocrine therapy for women with breast cancer, whether tamoxifen or AI, increases the risk of death.

Original languageEnglish
Pages (from-to)1515-1524
Number of pages10
JournalBritish Journal of Cancer
Volume108
Issue number7
DOIs
Publication statusPublished - Apr 16 2013

Fingerprint

Cohort Studies
Breast Neoplasms
Recurrence
Mortality
Aromatase Inhibitors
Tamoxifen
Therapeutics
Clinical Audit
Cancer Care Facilities
Death Certificates
Hospital Records
Scotland
Survival Analysis
Estrogen Receptors
Registries
Retrospective Studies
Confidence Intervals
Survival
Neoplasms

All Science Journal Classification (ASJC) codes

  • Cancer Research
  • Oncology

Cite this

Makubate, B. ; Donnan, P. T. ; Dewar, J. A. ; Thompson, A. M. ; McCowan, C. / Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality. In: British Journal of Cancer. 2013 ; Vol. 108, No. 7. pp. 1515-1524.
@article{065956e40cea4fec89336470e2d0b0b8,
title = "Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality",
abstract = "Background:Adjuvant endocrine therapy is recommended for women with oestrogen receptor-positive breast cancer, but many women do not take the medication as directed and they stop treatment before completing the standard 5-year duration.Methods:This retrospective cohort study conducted between 1993 and 2008 of all women with incident breast cancer, who are residing in the Tayside region of Scotland, examined adherence to prescribed adjuvant tamoxifen or aromatase inhibitors (AIs). Survival analysis examined the effect of adherence on all-cause mortality, breast cancer death and recurrence, using linked prescribing, cancer registry, clinical cancer audit, hospital discharge and death records.Results:A total of 3361 women with breast cancer were followed for a median 4.47 years (interquartile range (IQR)=2.04-8.55). The median overall adherence was 90{\%} (IQR=90-100{\%}), but the annual adherence reduced after a longer period from diagnosis. Low adherence of <80{\%} was associated with poorer survival (hazard ratios=1.20; 95{\%} confidence interval=1.03-1.40, P=0.019). There was no significant difference for low adherence over the treatment period and recurrence, or breast cancer death, but patients with high annual adherence for 5 years had better outcomes than those with 3 or less.Conclusion:Low adherence to all adjuvant endocrine therapy for women with breast cancer, whether tamoxifen or AI, increases the risk of death.",
author = "B. Makubate and Donnan, {P. T.} and Dewar, {J. A.} and Thompson, {A. M.} and C. McCowan",
year = "2013",
month = "4",
day = "16",
doi = "10.1038/bjc.2013.116",
language = "English",
volume = "108",
pages = "1515--1524",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "7",

}

Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality. / Makubate, B.; Donnan, P. T.; Dewar, J. A.; Thompson, A. M.; McCowan, C.

In: British Journal of Cancer, Vol. 108, No. 7, 16.04.2013, p. 1515-1524.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality

AU - Makubate, B.

AU - Donnan, P. T.

AU - Dewar, J. A.

AU - Thompson, A. M.

AU - McCowan, C.

PY - 2013/4/16

Y1 - 2013/4/16

N2 - Background:Adjuvant endocrine therapy is recommended for women with oestrogen receptor-positive breast cancer, but many women do not take the medication as directed and they stop treatment before completing the standard 5-year duration.Methods:This retrospective cohort study conducted between 1993 and 2008 of all women with incident breast cancer, who are residing in the Tayside region of Scotland, examined adherence to prescribed adjuvant tamoxifen or aromatase inhibitors (AIs). Survival analysis examined the effect of adherence on all-cause mortality, breast cancer death and recurrence, using linked prescribing, cancer registry, clinical cancer audit, hospital discharge and death records.Results:A total of 3361 women with breast cancer were followed for a median 4.47 years (interquartile range (IQR)=2.04-8.55). The median overall adherence was 90% (IQR=90-100%), but the annual adherence reduced after a longer period from diagnosis. Low adherence of <80% was associated with poorer survival (hazard ratios=1.20; 95% confidence interval=1.03-1.40, P=0.019). There was no significant difference for low adherence over the treatment period and recurrence, or breast cancer death, but patients with high annual adherence for 5 years had better outcomes than those with 3 or less.Conclusion:Low adherence to all adjuvant endocrine therapy for women with breast cancer, whether tamoxifen or AI, increases the risk of death.

AB - Background:Adjuvant endocrine therapy is recommended for women with oestrogen receptor-positive breast cancer, but many women do not take the medication as directed and they stop treatment before completing the standard 5-year duration.Methods:This retrospective cohort study conducted between 1993 and 2008 of all women with incident breast cancer, who are residing in the Tayside region of Scotland, examined adherence to prescribed adjuvant tamoxifen or aromatase inhibitors (AIs). Survival analysis examined the effect of adherence on all-cause mortality, breast cancer death and recurrence, using linked prescribing, cancer registry, clinical cancer audit, hospital discharge and death records.Results:A total of 3361 women with breast cancer were followed for a median 4.47 years (interquartile range (IQR)=2.04-8.55). The median overall adherence was 90% (IQR=90-100%), but the annual adherence reduced after a longer period from diagnosis. Low adherence of <80% was associated with poorer survival (hazard ratios=1.20; 95% confidence interval=1.03-1.40, P=0.019). There was no significant difference for low adherence over the treatment period and recurrence, or breast cancer death, but patients with high annual adherence for 5 years had better outcomes than those with 3 or less.Conclusion:Low adherence to all adjuvant endocrine therapy for women with breast cancer, whether tamoxifen or AI, increases the risk of death.

UR - http://www.scopus.com/inward/record.url?scp=84876496508&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876496508&partnerID=8YFLogxK

U2 - 10.1038/bjc.2013.116

DO - 10.1038/bjc.2013.116

M3 - Article

VL - 108

SP - 1515

EP - 1524

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 7

ER -